MedTrace Logo

EASI Access II --- Follow-up Study to the EASI Access Trial

NCT00740727 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2009-09-11

Study results available
· View outcomes & findings →

Summary

Test whether Basic Life Support (BLS) providers can successfully place Enzymatically Augmented Subcutaneous Infusion (EASI) Access lines for subcutaneous infusion, and characterize intravascular absorption of EASI-administered (tracer-labelled) glucose (D5W).

Conditions

  • Disaster Medicine
  • Difficult Intravenous Access
  • Dehydration

Interventions

DRUG

Human recombinant hyaluronidase (HRH)

150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)

PROCEDURE

Enzymatically Augmented Subcutaneous Infusion (EASI) line placement

Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.

Sponsors & Collaborators

  • Baxter Healthcare Corporation

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Stephen H Thomas, MD MPH · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00740727 on ClinicalTrials.gov